<p>/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)（&#34;BioMarin&#34;）今天宣布，计划在市场和其他条件允许的情况下，发行 8.5 亿美元的 2034 年到期的高级无担保债券（&#34;债券&#34;）。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/534018/BioMarin_Pharmaceutical_Inc_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/534018/BioMarin_Pharmaceutical_Inc_Logo.jpg"/></p>
<p>BioMarin 还宣布，针对即将收购 Amicus Therapeutics, Inc.（&#34;Amicus&#34;）的交易（&#34;收购&#34;），启动了一项新的 20 亿美元高级担保定期贷款&#34;B&#34;设施（&#34;定期贷款 B 设施&#34;），该定期贷款 B 设施是对 800 百万美元高级担保定期贷款&#34;A&#34;设施（&#34;定期贷款 A 设施&#34;，与定期贷款 B 设施合称为&#34;定期贷款设施&#34;）和 600 百万美元高级担保循环信贷设施的补充，BioMarin 预计将在收购中进入该循环信贷设施（&#34;新循环信贷设施&#34;，与定期贷款设施合称为&#34;新高级担保信贷设施&#34;）。</p>
<p>BioMarin 计划将债券发行的净收益与定期贷款设施的借款和手头现金一起，用于支付与收购相关的对价及相关费用，借款于新高级担保信贷设施，以及债券的发行。公司还可能在新循环信贷设施下借款最多 1.5 亿美元以支付这些费用和支出。</p>
<p>债券发行的总收益将在发行结束时存入一个托管账户，待收购完成。如果收购未能在 2026 年 12 月 19 日或之前完成，或在发生某些其他事件时，BioMarin 将被要求以债券初始发行价格的 100% 加上自发行之日起应计未付利息的赎回价格赎回所有债券，或至最近支付或提供利息的日期，但不包括特别强制赎回日期。</p>
<p>债券将由 BioMarin 的某些子公司共同和分别担保，这些子公司将在新高级担保信贷设施下担保义务，包括在收购结束后，Amicus 及其某些子公司将担保新高级担保信贷设施下的义务。</p>
<p>债券的契约预计将包含惯常的约定，其中包括在某些例外情况下，限制 BioMarin 及其子公司承担额外债务、支付股息、进行某些其他限制性支付、承担担保债务、处置资产、进行合并和收购或出售或转让其全部或大部分资产的能力。</p>
<p>债券将不会根据 1933 年证券法（&#34;证券法&#34;）或任何州或其他证券法进行注册，且在没有有效注册声明或适用的注册豁免的情况下，可能不会在美国提供或出售。因此，债券的发行仅适用于有限数量的被合理认为是&#34;合格机构买家&#34;（根据证券法第 144A 条的定义）或根据证券法第 S 条在美国以外的非美国人士。债券将受到转让和转售的限制，除非符合证券法的注册要求或根据豁免进行转让，并遵守任何州或其他适用的证券法。</p>
<p>本新闻稿仅供信息参考，不构成或不形成购买、获取、认购、出售或以其他方式处置任何证券的要约、邀请或要约的部分，也不构成在任何司法管辖区内根据拟议交易或其他情况的投票或批准的征求，也不应在任何司法管辖区内违反适用法律进行证券的销售、发行或转让。本新闻稿包含有关债券即将发行的信息，且无法保证该发行将完成。债券的发行仅可通过发行备忘录进行。</p>
<p><strong>关于 BioMarin</strong></p>
<p>BioMarin 是一家领先的全球罕见疾病生物技术公司，专注于为生活在基因定义条件下的人们提供药物。公司成立于 1997 年，总部位于加利福尼亚州圣拉斐尔，拥有创新的良好记录，拥有八种商业疗法和强大的临床及临床前管线。BioMarin 采用独特的药物发现和开发方法，旨在释放基因科学的全部潜力，追求具有深远影响的类别定义药物。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含关于拟议的票据发行、新的高级担保信贷设施的签署、生物玛琳（BioMarin）计划发行票据及预计收益用途的前瞻性声明。这些前瞻性声明是预测，涉及风险和不确定性，因此实际结果可能与这些声明有重大差异。这些风险和不确定性包括但不限于完成拟议的票据发行、新的高级担保信贷设施和收购的时间，以及这些交易可能无法完成的风险，以及生物玛琳在证券交易委员会的备案文件中详细列出的因素，包括但不限于在生物玛琳截至 2025 年 9 月 30 日的季度报告（Form 10-Q）中 “风险因素” 标题下包含的因素，这些因素可能会在后续报告中更新。投资者被敦促不要过度依赖前瞻性声明，这些声明仅在本日期有效。生物玛琳没有义务，并明确声明不承担更新或更改任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因，法律要求的情况除外。</p>
<p>BioMarin® 是生物玛琳制药公司（BioMarin Pharmaceutical Inc.）的注册商标。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>联系人：</strong></td>
<td></td>
</tr>
<tr>
<td>投资者</td>
<td>媒体</td>
</tr>
<tr>
<td><em>Traci McCarty</em></td>
<td><em>Erin Rau</em></td>
</tr>
<tr>
<td><em>生物玛琳制药公司</em></td>
<td><em>生物玛琳制药公司</em></td>
</tr>
<tr>
<td><em>(415) 455-7558</em></td>
<td>(925) 683-9622</td>
</tr>
</tbody>
</table>
<p>来源：生物玛琳制药公司（BioMarin Pharmaceutical Inc.）</p>

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

<p>拜玛林制药（BioMarin Pharmaceutical Inc.）计划发行 8.5 亿美元的 2034 年到期高级无担保债券，并已启动一项 20 亿美元的高级担保定期贷款的联合安排，以支持其收购 Amicus Therapeutics。所得款项将用于收购及相关费用。该债券将由某些子公司提供担保，并受到转让限制。此公告仅为信息性内容，不构成出售证券的要约</p>

<p>, /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (&#34;BioMarin&#34;) announced today that it intends to offer, subject to market and other conditions, $850 million of senior unsecured notes due 2034 (the &#34;Notes&#34;).</p>
<div class="lb-trans"><p>/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)（&#34;BioMarin&#34;）今天宣布，计划在市场和其他条件允许的情况下，发行 8.5 亿美元的 2034 年到期的高级无担保债券（&#34;债券&#34;）。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/534018/BioMarin_Pharmaceutical_Inc_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/534018/BioMarin_Pharmaceutical_Inc_Logo.jpg"/></p>
<p>BioMarin also announced that, in connection with the pending acquisition (the &#34;Acquisition&#34;) of Amicus Therapeutics, Inc. (&#34;Amicus&#34;), it launched the syndication of a new $2 billion senior secured term loan &#34;B&#34; facility (the &#34;Term Loan B Facility&#34;), which Term Loan B Facility is in addition to a $800 million senior secured term loan &#34;A&#34; facility (the &#34;Term Loan A Facility&#34; and, together with the Term Loan B Facility, the &#34;Term Facilities&#34;), and a $600 million senior secured revolving credit facility into which BioMarin expects to enter in connection with the Acquisition (the &#34;New Revolving Facility&#34; and, together with the Term Facilities, the &#34;New Senior Secured Credit Facilities&#34;).</p>
<div class="lb-trans"><p>BioMarin 还宣布，针对即将收购 Amicus Therapeutics, Inc.（&#34;Amicus&#34;）的交易（&#34;收购&#34;），启动了一项新的 20 亿美元高级担保定期贷款&#34;B&#34;设施（&#34;定期贷款 B 设施&#34;），该定期贷款 B 设施是对 800 百万美元高级担保定期贷款&#34;A&#34;设施（&#34;定期贷款 A 设施&#34;，与定期贷款 B 设施合称为&#34;定期贷款设施&#34;）和 600 百万美元高级担保循环信贷设施的补充，BioMarin 预计将在收购中进入该循环信贷设施（&#34;新循环信贷设施&#34;，与定期贷款设施合称为&#34;新高级担保信贷设施&#34;）。</p>
</div><p>BioMarin intends to use the net proceeds from the offering of the Notes, together with borrowings under the Term Facilities and cash on hand, to fund the consideration payable in connection with the Acquisition and related fees and expenses in connection with the Acquisition, the borrowings under the New Senior Secured Credit Facilities, and the issuance of the Notes. The company may also borrow up to $150 million under the New Revolving Facility to pay such fees and expenses.</p>
<div class="lb-trans"><p>BioMarin 计划将债券发行的净收益与定期贷款设施的借款和手头现金一起，用于支付与收购相关的对价及相关费用，借款于新高级担保信贷设施，以及债券的发行。公司还可能在新循环信贷设施下借款最多 1.5 亿美元以支付这些费用和支出。</p>
</div><p>Gross proceeds from the issuance of the Notes will be deposited into an escrow account at the closing of the Offering, pending consummation of the Acquisition. In the event that the Acquisition is not completed on or prior to December 19, 2026, or upon the occurrence of certain other events, BioMarin will be required to redeem all of the Notes at a redemption price equal to 100% of the initial issue price of the Notes plus accrued and unpaid interest from the date of issuance, or the most recent date to which interest has been paid or provided for, to but excluding the special mandatory redemption date.</p>
<div class="lb-trans"><p>债券发行的总收益将在发行结束时存入一个托管账户，待收购完成。如果收购未能在 2026 年 12 月 19 日或之前完成，或在发生某些其他事件时，BioMarin 将被要求以债券初始发行价格的 100% 加上自发行之日起应计未付利息的赎回价格赎回所有债券，或至最近支付或提供利息的日期，但不包括特别强制赎回日期。</p>
</div><p>The Notes will be jointly and severally guaranteed by certain of BioMarin's subsidiaries that will guarantee the obligations under the New Senior Secured Credit Facilities, including, after the closing of the Acquisition, Amicus and certain of its subsidiaries that will guarantee the obligations under the New Senior Secured Credit Facilities.</p>
<div class="lb-trans"><p>债券将由 BioMarin 的某些子公司共同和分别担保，这些子公司将在新高级担保信贷设施下担保义务，包括在收购结束后，Amicus 及其某些子公司将担保新高级担保信贷设施下的义务。</p>
</div><p>The indenture governing the Notes is expected to contain customary covenants that, among other things, restrict, with certain exceptions, the ability of each of BioMarin and its subsidiaries to incur additional debt, pay dividends, make certain other restricted payments, incur debt secured by liens, dispose of assets, engage in consolidations and mergers or sell or transfer all or substantially all of its assets.</p>
<div class="lb-trans"><p>债券的契约预计将包含惯常的约定，其中包括在某些例外情况下，限制 BioMarin 及其子公司承担额外债务、支付股息、进行某些其他限制性支付、承担担保债务、处置资产、进行合并和收购或出售或转让其全部或大部分资产的能力。</p>
</div><p>The Notes will not be registered under the Securities Act of 1933, as amended (the &#34;Securities Act&#34;), or any state or other securities laws and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from the registration requirements of or in a transaction not subject to the Securities Act and any state or other applicable securities laws. Accordingly, the offering of the Notes is available only to a limited number of persons who are either (1) reasonably believed to be &#34;qualified institutional buyers&#34; as defined in Rule 144A under the Securities Act or (2) non-U.S. persons outside the United States pursuant to Regulation S under the Securities Act. The Notes will be subject to restrictions on transferability and resale and may not be transferred or resold except in compliance with the registration requirements of the Securities Act or pursuant to an exemption therefrom and in compliance with any state or other applicable securities laws.</p>
<div class="lb-trans"><p>债券将不会根据 1933 年证券法（&#34;证券法&#34;）或任何州或其他证券法进行注册，且在没有有效注册声明或适用的注册豁免的情况下，可能不会在美国提供或出售。因此，债券的发行仅适用于有限数量的被合理认为是&#34;合格机构买家&#34;（根据证券法第 144A 条的定义）或根据证券法第 S 条在美国以外的非美国人士。债券将受到转让和转售的限制，除非符合证券法的注册要求或根据豁免进行转让，并遵守任何州或其他适用的证券法。</p>
</div><p>This press release is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. This press release contains information about the pending offering of the Notes, and there can be no assurance that the offering will be completed. The offering of the Notes may be made only by means of an offering memorandum.</p>
<div class="lb-trans"><p>本新闻稿仅供信息参考，不构成或不形成购买、获取、认购、出售或以其他方式处置任何证券的要约、邀请或要约的部分，也不构成在任何司法管辖区内根据拟议交易或其他情况的投票或批准的征求，也不应在任何司法管辖区内违反适用法律进行证券的销售、发行或转让。本新闻稿包含有关债券即将发行的信息，且无法保证该发行将完成。债券的发行仅可通过发行备忘录进行。</p>
</div><p><strong>About BioMarin</strong></p>
<div class="lb-trans"><p><strong>关于 BioMarin</strong></p>
</div><p>BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.</p>
<div class="lb-trans"><p>BioMarin 是一家领先的全球罕见疾病生物技术公司，专注于为生活在基因定义条件下的人们提供药物。公司成立于 1997 年，总部位于加利福尼亚州圣拉斐尔，拥有创新的良好记录，拥有八种商业疗法和强大的临床及临床前管线。BioMarin 采用独特的药物发现和开发方法，旨在释放基因科学的全部潜力，追求具有深远影响的类别定义药物。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements about the proposed offering of the Notes, the entry into the New Senior Secured Credit Facilities, BioMarin's intention to issue the Notes and the expected use of proceeds. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others, the timing to consummate the proposed Notes offering, New Senior Secured Credit Facilities and Acquisition, and the risk that such transactions may not close, as well as those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption &#34;Risk Factors&#34; in BioMarin's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as such factors may be updated by any subsequent reports. Investors are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.</p>
<div class="lb-trans"><p>本新闻稿包含关于拟议的票据发行、新的高级担保信贷设施的签署、生物玛琳（BioMarin）计划发行票据及预计收益用途的前瞻性声明。这些前瞻性声明是预测，涉及风险和不确定性，因此实际结果可能与这些声明有重大差异。这些风险和不确定性包括但不限于完成拟议的票据发行、新的高级担保信贷设施和收购的时间，以及这些交易可能无法完成的风险，以及生物玛琳在证券交易委员会的备案文件中详细列出的因素，包括但不限于在生物玛琳截至 2025 年 9 月 30 日的季度报告（Form 10-Q）中 “风险因素” 标题下包含的因素，这些因素可能会在后续报告中更新。投资者被敦促不要过度依赖前瞻性声明，这些声明仅在本日期有效。生物玛琳没有义务，并明确声明不承担更新或更改任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因，法律要求的情况除外。</p>
</div><p>BioMarin® is a registered trademark of BioMarin Pharmaceutical Inc.</p>
<div class="lb-trans"><p>BioMarin® 是生物玛琳制药公司（BioMarin Pharmaceutical Inc.）的注册商标。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contacts:</strong></td>
<td></td>
</tr>
<tr>
<td>Investors</td>
<td>Media</td>
</tr>
<tr>
<td><em>Traci McCarty</em></td>
<td><em>Erin Rau</em></td>
</tr>
<tr>
<td><em>BioMarin Pharmaceutical Inc.</em></td>
<td><em>BioMarin Pharmaceutical Inc.</em></td>
</tr>
<tr>
<td><em>(415) 455-7558</em></td>
<td>(925) 683-9622</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>联系人：</strong></td>
<td></td>
</tr>
<tr>
<td>投资者</td>
<td>媒体</td>
</tr>
<tr>
<td><em>Traci McCarty</em></td>
<td><em>Erin Rau</em></td>
</tr>
<tr>
<td><em>生物玛琳制药公司</em></td>
<td><em>生物玛琳制药公司</em></td>
</tr>
<tr>
<td><em>(415) 455-7558</em></td>
<td>(925) 683-9622</td>
</tr>
</tbody>
</table>
</div><p>SOURCE BioMarin Pharmaceutical Inc.</p>
<div class="lb-trans"><p>来源：生物玛琳制药公司（BioMarin Pharmaceutical Inc.）</p>
</div>

BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility | BMRN Stock News

StockTitan

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

拜玛林制药

基因改革 ETF - ARK

Invesco Nasdaq Biotechnology ETF

纳斯达克生物科技指数 ETF - iShares Nasdaq

美国制药 ETF - iShares

医药突破 ETF - ALPS

拜玛林制药宣布计划进行高级票据的私人发售，并为新的高级担保定期贷款融资进行银团 | BMRN 股票新闻